Yang Z, Liang SQ, Saliakoura M, Yang H, Vassella E, Konstantinidou G, Tschan M, Hegedüs B, Zhao L, Gao Y, Xu D, Deng H, Marti TM, Kocher GJ, Wang W, Schmid RA, Peng RW. Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer. EMBO Mol Med. 2021 Aug 8:e13193. doi: 10.15252/emmm.202013193. Epub ahead of print. PMID: 34369083.

Brügger M, Démoulins T, Barut GT, Zumkehr B, Oliveira Esteves BI, Mehinagic K, Haas Q, Schögler A, Rameix-Welti MA, Eléouët JF, Moehrlen U, Marti TM, Schmid RA, Summerfield A, Posthaus H, Ruggli N, Hall SRR, Alves MP. Pulmonary mesenchymal stem cells are engaged in distinct steps of host response to respiratory syncytial virus infection. PLoS Pathog. 2021 Jul 28;17(7):e1009789. doi: 10.1371/journal.ppat.1009789. PMID: 34320038; PMCID: PMC8351988.

Gao Y, Zens P, Su M, Gemperli CA, Yang H, Deng H, Yang Z, Xu D, Hall SRR, Berezowska S, Dorn P, Peng RW, Schmid RA, Wang W, Marti TM. Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR). J Exp Clin Cancer Res. 2021 Apr 19;40(1):138. doi: 10.1186/s13046-021-01938-2. PMID: 33874986; PMCID: PMC8056724.

Xu D, Liang SQ, Yang Z, Yang H, Bruggmann R, Oberhaensli S, Berezowska S, Marti TM, Hall SRR, Dorn P, Kocher GJ, Schmid RA, Peng RW. Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. Cell Death Dis. 2021 Apr 15;12(4):406. doi: 10.1038/s41419-021-03668-x. PMID: 33859162; PMCID: PMC8050302.

Yang Z, Liang SQ, Yang H, Xu D, Bruggmann R, Gao Y, Deng H, Berezowska S, Hall SRR, Marti TM, Kocher GJ, Zhou Q, Schmid RA, Peng RW. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer. Cancer Res. 2021 Jun 1;81(11):3121-3133. doi: 10.1158/0008-5472.CAN-20-2276. Epub 2021 Mar 8. PMID: 33685992.


Yang H, Yao F, Marti TM, Schmid RA, Peng RW. Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity. Cancers (Basel). 2020 Nov 16;12(11):3389. doi: 10.3390/cancers12113389. PMID: 33207636; PMCID: PMC7698146.

Yang H, Zhao L, Gao Y, Yao F, Marti TM, Schmid RA, Peng RW. Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer. Cancers (Basel). 2020 Nov 5;12(11):3273. doi: 10.3390/cancers12113273. PMID: 33167414; PMCID: PMC7694346.

Wang L, Dorn P, Simillion C, Froment L, Berezowska S, Tschanz SA, Haenni B, Blank F, Wotzkow C, Peng RW, Marti TM, Bode PK, Moehrlen U, Schmid RA, Hall SRR. EpCAM+CD73+ mark epithelial progenitor cells in postnatal human lung and are associated with pathogenesis of pulmonary disease including lung adenocarcinoma. Am J Physiol Lung Cell Mol Physiol. 2020 Nov 1;319(5):L794-L809. doi: 10.1152/ajplung.00279.2019. Epub 2020 Jul 29. PMID: 32726135.

Wang L, Dorn P, Zeinali S, Froment L, Berezowska S, Kocher GJ, Alves MP, Brügger M, Esteves BIO, Blank F, Wotzkow C, Steiner S, Amacker M, Peng RW, Marti TM, Guenat OT, Bode PK, Moehrlen U, Schmid RA, Hall SRR. CD90+CD146+ identifies a pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lung. Am J Physiol Lung Cell Mol Physiol. 2020 Apr 1;318(4):L813-L830. doi: 10.1152/ajplung.00146.2019. Epub 2020 Feb 19. PMID: 32073879.

Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ, Schmid RA, Peng RW. CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Mol Cancer Ther. 2020 Feb;19(2):661-672. doi: 10.1158/1535-7163.MCT-19-0724. Epub 2019 Nov 6. PMID: 31694888.


Xu D, Yang H, Yang Z, Berezowska S, Gao Y, Liang SQ, Marti TM, Hall SRR, Dorn P, Kocher GJ, Schmid RA, Peng RW. Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers (Basel). 2019 Oct 8;11(10):1502. doi: 10.3390/cancers11101502. PMID: 31597321; PMCID: PMC6827154.

Yang H, Liang SQ, Xu D, Yang Z, Marti TM, Gao Y, Kocher GJ, Zhao H, Schmid RA, Peng RW. HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. Oncogenesis. 2019 Aug 20;8(9):45. doi: 10.1038/s41389-019-0158-7. PMID: 31431614; PMCID: PMC6702198.

Gao Y, Dorn P, Liu S, Deng H, Hall SRR, Peng RW, Schmid RA, Marti TM. Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. Cancer Cell Int. 2019 Nov 29;19:317. doi: 10.1186/s12935-019-1037-1. PMID: 31798346; PMCID: PMC6883680.

Tièche CC, Gao Y, Bührer ED, Hobi N, Berezowska SA, Wyler K, Froment L, Weis S, Peng RW, Bruggmann R, Schär P, Amrein MA, Hall SRR, Dorn P, Kocher G, Riether C, Ochsenbein A, Schmid RA, Marti TM. Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. Neoplasia. 2019 Feb;21(2):185-196. doi: 10.1016/j.neo.2018.09.008. Epub 2018 Dec 27. PMID: 30591423; PMCID: PMC6309124.

Liang SQ, Bührer ED, Berezowska S, Marti TM, Xu D, Froment L, Yang H, Hall SRR, Vassella E, Yang Z, Kocher GJ, Amrein MA, Riether C, Ochsenbein AF, Schmid RA, Peng RW. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene. 2019 Jan;38(5):622-636. doi: 10.1038/s41388-018-0479-6. Epub 2018 Aug 31. PMID: 30171261.